Effects of pertussis toxin, dibutyryl-cyclic-AMP, bromo-cyclic-AMP and forskolin on the behavioural and electrocortical power spectrum changes induced by microinfusion of interleukin-2 into the locus coeruleus.
Human recombinant interleukin-2 and rat recombinant IL-2 microinjected into the locus coeruleus of rats, induced typical dose-dependent behavioural sedation and/or sleep and electrocortical synchronization. During sleep induced by this lymphokine a dose-dependent increase in total voltage power (0.25-16 Hz) as well as in the 0.25-3, 3-6 and 6-9 Hz frequency bands was observed. The behavioural and electrocortical effects of interleukin-2 were blocked in animals pretreated with anti-IL-2 monoclonal antibodies and with naloxone, whereas they were still evident in rats pretreated with yohimbine. In addition, the behavioural and electrocortical slow-wave sleep effects observed after the administration of interleukin-2 into the locus coeruleus were reduced significantly or antagonized completely by a previous pretreatment with pertussis toxin, forskolin, dibutyryl-cyclic-AMP and 8-bromo-cyclic-AMP. These results are consistent with the hypothesis that the behavioural and electrocortical changes of this lymphokine are mediated at locus coeruleus level via a guanine regulatory Gi protein coupling IL-2 specific receptors to the adenylate cyclase system.
De Sarro
G
G
Institute of Pharmacology, Faculty of Medicine, University of Catanzaro, Italy.
Nisticó
G
G
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology*; D037361:Adenylate Cyclase Toxin; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001522:Behavior, Animal / Q000187:drug effects*; D003994:Bucladesine / Q000494:pharmacology*; D005576:Colforsin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D008125:Locus Coeruleus; D008297:Male; D008845:Microinjections; D009270:Naloxone / Q000494:pharmacology; D037342:Pertussis Toxin; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000494:pharmacology; D010566:Virulence Factors, Bordetella / Q000494:pharmacology*; D015016:Yohimbine / Q000494:pharmacology
D037361:Adenylate Cyclase Toxin; D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D011994:Recombinant Proteins; D010566:Virulence Factors, Bordetella; D005576:Colforsin; D015124:8-Bromo Cyclic Adenosine Monophosphate; D015016:Yohimbine; D009270:Naloxone; D003994:Bucladesine; D037342:Pertussis Toxin